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ditive effect. The resulting MFBs, relevant, for example, for 
tumor progression, generated a matrix scaffold rich in fibro-
nectin and galectin-1 that supported keratinocyte culture 
without feeder cells. Of note, keratinocytes cultured on this 
substratum presented a stem-like cell phenotype with small 
size and keratin-19 expression. In vivo in rats, galectin-1 had 
a positive effect on skin wound closure 21 days after surgery. 
In conclusion, we describe the differential potential of cer-
tain human galectins to induce the conversion of dermal fi-
broblasts into MFBs and the generation of a bioactive cell 
culture substratum.  Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Members of the galectin family of endogenous lectins are 
potent adhesion/growth-regulatory effectors. Their multi-
functionality opens possibilities for their use in bioapplica-
tions. We studied whether human galectins induce the con-
version of human dermal fibroblasts into myofibroblasts 
(MFBs) and the production of a bioactive extracellular matrix 
scaffold is suitable for cell culture. Testing a panel of galec-
tins of all three subgroups, including natural and engineered 
variants, we detected activity for the proto-type galectin-1 
and galectin-7, the chimera-type galectin-3 and the tandem-
repeat-type galectin-4. The activity of galectin-1 required 
the integrity of the carbohydrate recognition domain. It was 
independent of the presence of TGF-  1, but it yielded an ad-
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 Introduction 
 Stem cells hold an enormous therapeutic potential, but 
obstacles remain to be overcome for their successful clin-
ical application, for example, concerning the generation 
of a suitable microenvironment to maintain stemness 
and to ensure anchorage [Voog and Jones, 2010]. In this 
context, the components of the extracellular matrix 
(ECM) play pivotal roles in docking cells and engaging 
them in the complex molecular interplay essential for the 
cells’ functionality. As a consequence, aberrations in this 
complex network, either engineered in mice or detected 
in patients, can lead to diseases [Hennet, 2009; Honke 
and Taniguchi, 2009]. Such observations guide interest 
especially to the glycan part of the ECM, a highly versatile 
platform for coding biochemical information, as embod-
ied in the concept of the sugar code [Gabius, 2009]. In-
deed, simple monosaccharides used as a matrix, inspired 
by this bioactivity of glycans, can already serve as a bioac-
tive substratum, even substituting for feeder cells in the 
case of epidermal keratinocytes [Labský et al., 2003]. In 
order to achieve the natural complexity, it would be ideal 
to direct cells to produce suitable ECM using endogenous 
effectors.
 Toward this end, observations that an endogenous lec-
tin, such as galectin-1, has proven capable of promoting 
the attachment of diverse types of cells, also in concert 
with matrix glycoproteins or chitosan, have given our re-
search a clear direction [André et al., 1999; Chang et al., 
2004; Kadri et al., 2005]. This type of galectin binds the 
  5  1 -integrin, as well as the associated ganglioside GM1, 
that influences cell adhesion and growth [André et al., 
2007; Wang et al., 2009]. It can redirect gene expression, 
for example of   2(I) collagen via TGF-  /Smad3 signal-
ing, and the exposure of fetal skin or mesenchymal stem 
cells leads to conversion to the myogenic lineage and even 
mature myotubes in vitro [Goldring et al., 2002a, b; 
Fischer et al., 2005; Chan et al., 2006; Okano et al., 2008]. 
In addition to potential medical relevance, we have de-
tected a strong galectin-1 presence in the stroma of squa-
mous cell carcinomas and in healing wounds [Lacina et 
al., 2007; Klíma et al., 2009]. Here, the presence of myo-
fibroblasts (MFBs), a distinct type of fibroblast positive 
for   -smooth muscle actin, is frequent [Hinz 2007; De 
Wever et al., 2008]. Their generation by conversion in situ 
is assumed to be induced by TGF-  [Brenmoehl et al., 
2009], their presence then contributing to promote 
wound healing/contraction and tumor progression of 
squamous carcinoma cells. Obviously, the ECM of MFBs 
can be conducive in programming cell activities. This 
concept led us to test the hypothesis whether galectin-1 is 
involved in MFB and ECM generation and then to inves-
tigate its bioactivity as a culture substratum for human 
keratinocytes. In other words, galectin-1 was studied as a 
potential inducer of the conversion of adult dermal fibro-
blasts into MFBs, using TGF-  1 and TGF-  3 as positive 
controls. Following these experiments, we addressed the 
issue of measuring the profile of this activity within the 
family of human galectins. This family consists of three 
groups, which differ in the spatial presentation of the lec-
tin domain, with characteristic expression in human skin 
[Villalobo et al., 2006; Čada et al., 2009]. As a conse-
quence, homodimeric galectin-1, galectin-2 and galec-
tin-7, the chimeric galectin-3 and the tandem-repeat-type 
galectin-4 and galectin-8 were comparatively studied un-
der identical conditions. Natural variants, that is, trun-
cated galectin-3 after proteolytic removal of the stalk re-
gion and the two galectin-8 forms differing in linker 
length, as well as an engineered form of galectin-4 with-
out linker and a galectin-1 mutant without lectin activity, 
completed the test panel used in the present study. In ad-
dition to testing the ability of the lectins in the panel to 
induce MFBs and the capacity of their ECM to support 
keratinocyte culture and for wound healing in vivo, we 
also contribute to defining the extent of functional diver-
gence among these homologous endogenous lectins.
 Materials and Methods 
 Preparation of Galectins 
 Human galectins ( table 1 ), including the linkerless variant of 
galectin-4 and the E71Q mutant of galectin-1, were obtained by 
recombinant production and purified by affinity chromatogra-
phy on lactosylated Sepharose 4B (or Ni-CAM TM HC resin from 
Sigma, Munich, Germany, in the case of the His-tagged galectin-1 
mutant without lectin activity) as a crucial step [Gabius et al., 
1985], routinely followed by the removal of any lipopolysaccha-
ride contamination [Sarter et al., 2009]. Product analysis was per-
formed using one- and two-dimensional gel electrophoresis, gel 
filtration and mass spectrometry as well as hemagglutination, sol-
id-phase and cell assays to ascertain activity [André et al., 2006, 
2007, 2008; Beer et al., 2008]. Proteolytic truncation of galectin-3 
with cleavage at the Tyr106/Gly107 and Glu229/Ile230 peptide 
bonds was performed using collagenase digestion [Kopitz et al., 
2001; Kübler et al., 2008].
 The Influence of Galectins on Human Dermal Fibroblasts 
 Dermal fibroblasts were isolated from skin specimens ob-
tained from healthy donors with their informed consent (in 
agreement with the Helsinki Declaration after approval by the 
Local Ethical Committee) in the Department of Aesthetic Surgery 
(Charles University, 3rd Faculty of Medicine). Sterile solutions of 
human galectins were prepared in Dulbecco’s culture medium 
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(DMEM) containing 10% fetal calf serum and antibiotics (all 
from Biochrom, Berlin, Germany). Human dermal fibroblasts 
were seeded at a density of 2,000 cells/cm 2 and cultured for 3–4 
weeks. The culture medium was changed three times per week. 
The sensitivity of fibroblasts to TGF-  1/-  3 was tested at 10 ng/
ml, as described elsewhere [Brenmoehl et al., 2009]. The contribu-
tion of galectins to MFB formation was assessed by using galec-
tins ( table 1 ) in concentrations of 200, 300, 400 and 600 ng/ml. 
The additive effect of both galectin-1 and TGF-  1 (10   g/ml) was 
tested by incubating cells with both substances. The role of galec-
tin was, moreover, verified by application of 20   g/ml of a poly-
clonal anti-galectin-1 antibody, developed in our laboratory and 
carefully tested for lack of cross-reactivity with other types of ga-
lectins (please see below). To exclude the nonspecific effect of im-
munoglobulins, the commercial anti-thyroglobulin rabbit poly-
clonal antibody (Dako, Glostrup, Denmark) was also tested.
 Using a commercial ELISA kit (R&D Systems, Minneapolis, 
Minn., USA), the concentration of TGF-  1, the best-known in-
ducer of MFB formation, was measured in conditioned media 
from cultures of human dermal fibroblasts in the absence or pres-
ence of galectins in a Multiskan RC reader (Labsystem, Helsinki, 
Finland) at 450 nm.
 Human Keratinocytes and Their Culture on Matrices
Induced by Galectins 
 The ECM scaffolds produced by cells exposed to galectins on 
the surface of coverslips were tested as substrates for the culture 
of human keratinocytes obtained as described above. The cover-
slips with the three-dimensional scaffolds were incubated with 
sterile distilled water for 60 min to devitalize MFBs by osmotic 
shock (as ascertained by subsequent culture), then the supports 
were incubated with culture medium for 24 h to prevent osmotic 
stress during the subsequent culturing of keratinocytes. These 
cells were obtained from the same clinical source and under iden-
tical ethical conditions as the fibroblasts. They were seeded at a 
density of 40  ! 10 3 cells/cm 2 and cultured in keratinocyte me-
dium [Strnad et al., 2009] at 5% CO 2 and 37  °  C for 1 week. Part of 
these experimental acellular supports with three-dimensional 
ECM lattices was fixed with 0.25% glutaraldehyde (Sigma-Ald-
rich, Prague, Czech Republic) for 30 min at laboratory tempera-
ture. After extensive washing they were used as described above. 
Cells cultured on untreated coverslips were used as a control.
 Immunocytochemical Analysis of Cultured Cells 
 The staining procedure, including fluorescence profiling, had 
been described recently in detail [Szabo et al., 2009]. Briefly, the 
tested specimens were fixed with 2% buffered paraformaldehyde 
(pH 7.2–7.4) for 5 min and washed with PBS. The cells were per-
meabilized by exposure to Triton X-100 (Sigma-Aldrich), and sites 
for the antigen-independent adsorption of antibodies were 
blocked by bovine serum albumin and/or nonimmune porcine 
serum, serum application preventing the binding of antibodies 
via the interaction of the Fc fragments of immunoglobulins with 
cellular Fc receptors. Commercial antibodies were diluted as rec-
ommended by the suppliers. The primary and secondary antibod-
ies used in this study are summarized in  table 2 . The lack of cross-
reactivity of our homemade anti-galectin antibodies was ascer-
tained, if required, after af finity depletion on resin with 
covalenty conjugated galectins [Kaltner et al., 2002; Saal et al., 
2005]. The specificity of the immunohistochemical reaction was 
verified by the replacement of specific antibodies by an irrelevant 
antibody recognizing thyroglobulin instead of the first-step anti-
body and/or by the omission of the first-step antibody as well as 
by processing positive control specimens. Cell nuclei were coun-
terstained by 4’,6-diamidino-2-phenylindole (DAPI; Sigma-Ald-
rich). The specimens were mounted in Vectashield (Vector Lab-
oratories, Burlingame, Calif., USA) and inspected by an Eclipse 
90i fluorescence microscope (Nikon, Prague, Czech Republic) 
equipped with filter blocks for FITC, TRITC and DAPI, and a 
Cool-1300Q CCD camera (Vosskühler, Osnabrück, Germany); 
data were analyzed by a LUCIA 5.1 computer-assisted image anal-
ysis system (Laboratory Imaging, Prague, Czech Republic).
 Experimental Animals and in vivo Study 
 The study design with 1-year-old male Sprague-Dawley rats 
(n = 48) was approved by the Ethical Committee of the Faculty of 
Medicine of Šafárik University and by the State Veterinary Ad-
ministration of the Slovak Republic. Surgery was performed un-
Table 1. G alectins used in experiments
Type of galectin Galectin Comment
Homodimeric galectin-1
(proto-type) galectin-1-E71Q strongly reduced affinity for carbohydrates
galectin-2
galectin-7
Chimera galectin-3
galectin-3-truncated proteolytically processed form lacks the collagenase-sensitive N-terminal section, reduc-
ing ability for cross-linking
Tandem-repeat galectin-4-linkerless prototype-like galectin-4 with covalent domain linkage after engineered removal of the 
linker peptide
galectin-8-short different lengths of the linker
galectin-8-long
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der general anesthesia induced by the administration of ketamine 
(40 mg/kg; Narkamon a.u.v.; Spofa, Prague, Czech Republic), xy-
lazine (15 mg/kg; Rometar a.u.v.; Spofa) and tramadol (5 mg/kg; 
Tramadol-K; Krka, Novo Mesto, Slovenia). One full-thickness in-
cision, 4 cm long, was made on the back of each rat. Cranially and 
caudally from the incision, round full-thickness skin excisions,
1 cm in diameter, were performed. The incision was then closed 
using an intradermal running suture (Chiraflon 5/0; Chirmax, 
Prague, Czech Republic). Subsequently, the rats were randomly 
assigned to four groups: (1) testing wild-type galectin-1, (2) test-
ing the E71Q mutant, (3) testing full-length galectin-3 and (4) 
mock treatment. Wounds of rats from groups 1–3 were treated 
daily with the respective galectin starting from the day of surgery 
until the third postoperative day. All rats, including the control 
group, were kept in cages with an oval opening over the wound to 
ensure similar levels of stress for each animal during the experi-
ment.
 The healing of wounds was measured from standardized pho-
tographs as follows. Wounds were photographed with a scale im-
mediately after surgery and at days 7 and 21 using an Olympus 
E330 digital camera equipped with a digital ED 50 mm f 2.0 mac-
ro objective and a ring set flash SRF-11 (Olympus, Tokyo, Japan). 
The wound area was then measured on the images using Quick 
Photo Micro 2.2 software (Premiere, Prague, Czech Republic) and 
expressed as a percentage of the original wound area generated on 
the day of surgery to reflect the level of wound healing. Statistical 
processing of the measured data was done using one-way ANOVA 
followed by the Tuckey-Kramer post hoc test. The quality of 
wound healing was evaluated in paraffin-embedded sections 
stained with hematoxylin-eosin.
 Results 
 In vitro Experiments 
 Galectins Induce MFB Formation 
 Cultures of normal dermal fibroblasts contained none 
or only a very limited number of MFBs ( fig. 1 a, b). To test 
the effector activity of the galectins, we systematically 
used galectin-1 and detected a significant increase in the 
number of MFBs in the third week of culture ( fig.  1 c). 
Next, we tested all the selected galectins (galectin-1, ga-
lectin-1-E71Q mutant, galectin-2, galectin-3, truncated 
version of galectin-3, galectin-4, linkerless variant of ga-
lectin-4 and both, that is, short and long, versions of ga-
lectin-8) in the concentration range of 200–800 ng/ml 
over the course of 3 weeks. The experiments revealed that 
the activity depends on the type of galectin and its con-
centration ( fig. 2 a–f). The strongest induction of the con-
version of fibroblasts to MFBs was achieved using ho-
modimeric galectin-1 ( fig.  2 a). Impairing its carbohy-
drate-binding activity by introducing the E71Q mutation 
led to a drastic reduction of its stimulatory ability ( fig. 2 b). 
Activity was also found for galectin-3, depending on the 
presence of the N-terminal stalk, because the truncated 
version of this galectin was inactive ( fig. 2 c, d). The natu-
ral version of tandem-repeat galectin-4 ( fig. 2 e) was also 
active concerning MFB formation. Parallel experiments 
Table 2. P rimary and secondary antibodies 
Antigen Type of antibody Source
Gal-1, Gal-2, Gal-3, Gal-4, Gal-7 rabbit polyclonal Faculty of Veterinary Medicine, Ludwig-Maximilians-University,
Munich, Germany
Gal-1 mouse monoclonal Vector Laboratories, Burlingame, Calif., USA
Fibronectin rabbit polyclonal Dako
Fibronectin mouse monoclonal Abcam, Cambridge, UK 
Collagen-1 mouse monoclonal Sigma-Aldrich, Prague, Czech Republic
Collagen-3 mouse monoclonal
Smooth muscle actin mouse monoclonal Dako
Keratin (wide spectrum) rabbit polyclonal Abcam
Keratin-19 mouse monoclonal Dako
Thyroglobulin mouse monoclonal
Thyroglobulin rabbit polyclonal
Rabbit immunoglobulins FITC-labeled swine serum Alseva, Prague, Czech Republic
Mouse immunoglobulins FITC-labeled swine serum
Mouse immunoglobulins TRITC-labeled goat serum Sigma-Aldrich
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with its linkerless variant delineated the importance of 
this part of the protein for bioactivity, because this ver-
sion of galectin-4 was inactive (not shown). Galectin-7, as 
the second representative of homodimeric galectins, was 
also able to stimulate MFB formation ( fig. 2 f). Galectin-2, 
as the closest relative of galectin-1, was not a significant 
activator of MFB formation, similarly as both natural 
forms of tandem-repeat-type galectin-8 (not shown).
 Obviously, certain galectins can serve as effectors for 
the conversion of dermal fibroblasts to MFBs, an activity 
known for TGF-  . Thus, we proceeded to determine 
whether these two types of inductors may act additively. 
Since galectins may act via inducing the secretion of 
TGF-  1 by cultured fibroblasts, we first determined the 
concentration of TGF-  1 in conditioned media, that is, 
controls and samples from cultures in the presence of ga-
lectin-1, galectin-3 and galectin-7. Except for two values 
( fig.  3 ), detectable concentrations of TGF-  1 were evi-
dently not reached. Comparing these data with the phys-
iological levels of TGF-  1 in serum [Lin et al., 2009] and 
with the concentration necessary for conversion (10 ng/
ml), the measured data provided no evidence for TGF-  1 
secretion upon galectin presence ( fig.  3 ). As expected, 
both TGF-  1 and TGF-  3 induced dermal fibroblasts to 
generate MFBs ( fig. 1 c–f). When galectin-1 was added to 
medium containing TGF-  1, an additive effect was ob-
served ( fig. 1 c, g, h). An antibody against the lectin strong-
ly reduced the formation of MFBs ( fig. 1 i).
d e f
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a b 50 μm
 Fig. 1. Detection of smooth muscle actin in control cultures of 
dermal fibroblasts ( a ,  b ) and illustration of the influence of TGF-
  1 and galectin-1 (200 ng/ml) on the formation of smooth muscle 
actin-positive myofibroblasts. The number of myofibroblasts was 
estimated as percentage of the number of cell nuclei occurring in 
smooth muscle actin-positive myofibroblast clusters related to the 
total number of nuclei in the evaluated area in three independent 
experiments. The representative figures demonstrating at the 
same level of magnification the control culture ( d ), the effect of 
TGF-  1 ( e ), TGF-  3 ( f ), combination of TGF-  1 with two con-
centrations of galectin-1 ( c ,  g ,  h ) and with antibody neutralizing 
galectin-1 are also included ( i ). The results show that myofibro-
blasts with low extent of smooth muscle actin expression are very 
rarely present in control (untreated) cultures of dermal fibroblasts 
( a ,  b , encircled). While the number of myofibroblasts is very low 
and stable in control cultures ( a–d ) during the testing period, 
TGF-  1 ( c ,  e ), TGF-  3 ( f ) and galectin-1 ( c ) have stimulatory ef-
fect on myfibroblast formation, with additive effect when both 
substances were applied simultaneously ( c ,  g ,  h ), the TGF being 
added to the system at the beginning of cell culture. The introduc-
tion of anti-galectin-1 antibody to the system, in which both the 
TGF-  1 and galectin-1 were applied simultaneously, strongly re-
duced the number of myofibroblasts ( i ). 
0
0
40
80
%
1 2 3 4
Weekc
TGF-1 + Gal-1
TGF-1
Control
Gal-1
i
200 ng/ml 300 ng/ml +a-Gal-1
TGF-1 + Gal-1 TGF-1 + Gal-1 TGF-1 + Gal-1
g h
 Dvořánková et al. Cells Tissues Organs 2011;194:469–480 474
200 ng/ml 300 ng/ml 400 ng/ml 600 ng/ml 800 ng/ml
G
al
-7
G
al
-4
G
al
-3
-T
ru
nc
G
al
-3
G
al
-1
G
al
-1
-E
71
Q
a
b
c
d
e
f
 Fig. 2. Influence of galectins (Gal), Gal-1, Gal-1-E71Q mutant, Gal-3, the proteolytically truncated Galectin-3 (Gal-3-Trunc), 
Gal-4 and Gal-7 on the formation of myfibroblasts detected by monitoring smooth muscle actin. Nuclei are counterstained by 
DAPI.  
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 Galectins Stimulate ECM Formation 
 We found that the presence of certain galectins led to 
the appearance of three-dimensional ECM scaffold 
( fig. 4 a–h). Namely, galectin-1, galectin-4 and galectin-7 
( fig. 4 b, c, d, g, h) were responsible for the marked produc-
tion of a complex three-dimensional network of fibers of 
140  8 60 nm in diameter. The galectin-1-E71Q mutant 
was not able to stimulate ECM production ( fig.  4 b–d). 
Other galectins, including galectin-3, were inactive 
( fig. 4 e, f). ECM fibers were composed from fibronectin 
( fig. 4 a–h,  5 a, b) and galectin-1 ( fig. 5 b, e) with colocaliza-
tion of these two proteins. When probing for collagen-1 
and collagen-3, only a very limited amount of collagen-1 
was detected in cultures of the stimulated cells ( fig. 5 c, d). 
Interestingly, using galectin-4 and galectin-7 as inductors, 
the cultured cells were able to produce an ECM enriched 
in galectin-1 but not in galectin-4 or galectin-7 ( fig. 5 e, f).
 ECM Scaffolds Produced by Galectin-Stimulated 
Fibroblasts Influence Phenotype of Cultured 
Keratinocytes 
 To determine whether such an ECM scaffold pro-
duced by fibroblasts/MFBs can find applications in cell 
culture, we next tested the panel of galectins given in the 
introduction in culture of keratinocytes without feeder 
cells. Keratinocytes cultured on these coverslips with a 
three-dimensional ECM network composed from fibro-
nectin and galectin-1 appeared to resorb this matrix 
( fig. 5 g). In comparison to control experiments ( fig. 5 h, i), 
the cells’ size was significantly smaller, and they ex-
pressed keratin-19 as one of the putative markers of poor-
ly differentiated keratinocytes. When the coverslips with 
the substratum were pretreated with glutaraldehyde to 
crosslink its components, the ECM lattices became resis-
tant to resorption, but the cells remained negative for ker-
atin-19 (not shown).
 In vivo Experiments 
 Galectins Influence Wound Healing 
 To take the observed in vitro activity to the in vivo 
level, we finally addressed the issue of rat skin-wound 
healing in the presence of galectins (galectin-1, galectin-
1-E71Q mutant, galectin-3). No remarkable effect on 
wound re-epithelialization was observed when the ani-
mals were treated with any of the tested galectins as the 
extent of re-epithelialization was identical with that seen 
with galectin-free controls and the wounds were com-
pletely re-epithelialized 3 weeks after the surgery ( fig. 
 6 a–d). Measuring the extent of wound contraction also 
revealed no effect of galectins at day 7, when wound re-
epithelialization was only partial. Continued observation 
revealed an effect for galectin-1. Compared to its control 
(E71Q), galectin-1 gave a positive result after 21 days, not 
seen for galectin-3 ( fig. 6 e–i).
 Discussion 
 Our study addresses four issues pertinent to evaluat-
ing the potential of galectins for application in cell-based 
and topical therapy modalities in a long-term perspec-
tive. Building on histopathological observations of the 
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 Fig. 3. Influence of wild-type galectin-1 
and its E71Q mutant on the concentration 
of TGF-  1 in cultures of normal dermal 
fibroblasts (DF). Two measured concen-
trations (arrows) are very low in compari-
son to the TGF-  1 concentration used for 
stimulating myofibroblast formation (x) 
and that found in normal plasma in hu-
mans (y). 
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presence of stromal galectin and the capacity of galec-
tin-1 to direct mesenchymal stem cells and fetal fibro-
blasts towards the myogenic lineage as described in the 
introduction, we tested this protein on adult dermal fi-
broblasts and found that it was able to convert them to 
MFBs at submicrogram/milliliter concentrations. Of 
note, this activity was abolished when the lectin site’s 
functionality was impaired by the E71Q mutation. The 
previously reported TGF-like activity of rat galectin-1 on 
DNA synthesis and anchorage-independent growth of 
3T3 cells, in contrast, was not sensitive to haptenic sugar 
inhibition [Yamaoka et al., 1993]. The induction of TGF-
  secretion as a downstream effector could be excluded, 
while an additive effect of galectin-1 and the growth fac-
tor could be documented.
 This ability of galectin-1 led us to monitor other hu-
man galectins, that is, to explore the functionality profile 
among these homologous proteins. We detected a con-
spicuous functional divergence within the class of proto-
type and tandem-repeat-type galectins. Also, a require-
ment for the presence of the stalk region in galectin-3, 
which is responsible for cross-linking activity, was seen. 
Evidently, even structurally closely related family mem-
bers can differ markedly in terms of functionality. Such 
divergence has previously been seen for the growth regu-
lation of human neuroblastoma and pancreatic carcino-
ma cells as well as activated T cells [Kopitz et al., 2001, 
2010; Sturm et al., 2004; Sanchez-Ruderisch et al., 2010]. 
Since galectin secretion can make these proteins available 
in the stroma, this described ability to increase the pres-
ence of MFBs may eventually contribute to tumor pro-
gression, analogously to TGF-  , for example in colon 
cancer where galectin-1 and galectin-4 in combination 
have a strongly negative impact on prognosis [Nagy et al., 
a b c d
e f g h
 Fig. 4. Immunocytochemical detection of fibronectin in control culture of dermal fibroblasts ( a ) and fibroblasts 
treated with galectin-1 in two concentrations ( b ,  c ), with mutated galectin-1 ( d ), galectin-3 ( e ), truncated ver-
sion of galectin-3 ( f ), galectin-4 ( g ) and galectin-7 ( h ) simultaneously. The extensive production of a three-di-
mensional fibronectin network was observed in cultures treated with galectin-1 (300 ng/ml,  c ), galectin-4 ( g ) 
or galectin-7 ( h ). 
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 Fig. 5. Influence of galectin-1 on the production of fibronectin 
(green signal,  a ,  b ) and a galectin-1 (red signal,  b )-containing 
three-dimensional network, compared to a weak effect on colla-
gen-1 synthesis (red signal,  c ) and a lack of effect on collagen-3 
synthesis (red signal,  d ). Analyzing the presence of fibronectin 
and galectin-1 ( b ), both proteins were detected and the distribu-
tion measured by fluorescence profiles. Other types of galectins 
such as galectin-7 also induced the production of galectin-1 
(green signal,  e ) but not of galectin-7 (green signal,  f ). Visualiza-
tion of smooth muscle actin (red signal,  a ,  e ,  f ) indicated that myo-
fibroblasts are located in the extracellular matrix network. When 
keratinocytes (red signal-keratin,  g ) were seeded on an ECM lat-
tice formed by galectin-1-induced fibroblasts/myofibroblasts, re-
sorption of ECM lattice was apparent (green signal, fibronectin, 
 g ). These keratinocytes were very small and expressed keratin-19 
(red signal,  h ) in addition to pan-kreatin (green,  h ). Keratinocytes 
cultured on coverslips are shown for comparison ( i ). Nuclei are 
counterstained by DAPI. 
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 Fig. 6. Effect of galectins on the re-epithelialization and contraction of skin wounds. Partial re-epithelialization 
as reached one week after the administration of galectin-1 ( a ) or galectin-3 ( b ). The double-headed arrow marks 
the distance between the wound margin (dotted line) and the edge of regenerating epithelium. The complete 
reaction is shown 3 weeks after the surgery ( c ,  d ). Galectins ( e–i ) stimulated wound contraction in comparison 
to physiological saline as a control ( e ,  i ) with the highest efficiency seen for wild-type galectin-1 ( f ,  i ), which 
surpassed the threshold for statistical significance after 3 weeks (p  ! 0.05). 
 Galectins and Tissue Engineering Cells Tissues Organs 2011;194:469–480 479
 References 
 André, S., S. Kojima, N. Yamazaki, C. Fink, H. 
Kaltner, K. Kayser, H.-J. Gabius (1999) Ga-
lectins-1 and -3 and their ligands in tumor 
biology. J Cancer Res Clin Oncol  125:  461–
474. 
 André, S., Z. Pei, H.-C. Siebert, O. Ramström, 
H.-J. Gabius (2006) Glycosyldisulfides from 
dynamic combinatorial libraries as O-glyco-
side mimetics for plant and mammalian lec-
tins: their reactivities in solid-phase and cell 
assays and conformational analysis by mo-
lecular dynamics simulations. Bioorg Med 
Chem  14:  6314–6323. 
 André, S., H. Sanchez-Ruderisch, H. Nakagawa, 
M. Buchholz, J. Kopitz, P. Forberich, W. 
Kemmner, C. Böck, K. Deguchi, K.M. De-
tjen, B. Wiedenmann, M. von Knebel Doe-
beritz, T.M. Gress, S.-I. Nishimura, S. Rose-
wicz, H.-J. Gabius (2007) Tumor suppressor 
p16 INK4a : modulator of glycomic profile and 
galectin-1 expression to increase susceptibil-
ity to carbohydrate-dependent induction of 
anoikis in pancreatic carcinoma cells. FEBS 
J  274: 3233–3256. 
 André, S., F. Sansone, H. Kaltner, A. Casnati, J. 
Kopitz, H.-J. Gabius, R. Ungaro (2008) 
Calix[n]arene-based glycoclusters: bioactiv-
ity of thiourea-linked galactose/lactose moi-
eties as inhibitors of binding of medically 
relevant lectins to a glycoprotein and cell-
surface glycoconjugates and selectivity 
among human adhesion/growth-regulatory 
galectins. ChemBioChem  9:  1649–1661. 
 Beer, A., S. André, H. Kaltner, M. Lensch, S. 
Franz, K. Sarter, C. Schulze, U.S. Gaipl, P. 
Kern, M. Herrmann, H.-J. Gabius (2008) Hu-
man galectins as sensors for apoptosis/ne-
crosis-associated surface changes of granu-
locytes and lymphocytes. Cytometry  73A: 
139–147. 
 Brenmoehl, J., S.N. Miller, C. Hofmann, D. Vogl, 
W. Falk, J. Schölmerich, G. Rogler (2009) 
Transforming growth factor-  1 induces in-
testinal myofibroblast differentiation and 
modulates their migration. World J Gastro-
enterol  15: 1431–1442. 
 Čada, Z., K. Smetana Jr, L. Lacina, Z. Plzáková, 
J. Štork, H. Kaltner, R. Russwurm, M. Lensch, 
S. André, H.-J. Gabius (2009) Immunohisto-
chemical fingerprinting of the network of 
seven adhesion/growth-regulatory lectins in 
human skin and detection of distinct tumor-
associated alterations. Folia Biol (Praha)  55: 
145–152. 
 Chan, J., K. O’Donoghue, M. Gavina, Y. Tor-
rente, N. Kennea, H. Mehmet, H. Stewart, 
D.J. Watt, J.E. Morgan, N.M. Fisk (2006) Ga-
lectin-1 induces skeletal muscle differentia-
tion in human fetal mesenchymal stem cells 
and increases muscle regeneration. Stem 
Cells  24: 1879–1891. 
 Chang, Y.-Y., S.-J. Cheb, H.-C. Liang, H.-W. 
Sung, C.-C. Lin, R.-R. Juany (2004) The ef-
fect of galectin-1 on 3T3 cell proliferation on 
chitosan membrane. Biomaterials  25:  3603–
3611. 
 De Wever, O., P. Demetter, M. Mareel, M. Bradle 
(2008) Stromal myofibroblasts are drivers of 
invasive cancer growth. Int J Cancer  123: 
 2229–2238. 
 Dvořánková, B., K. Smetana Jr., M. Chovanec, L. 
Lacina, J. Štork, Z. Plzáková, M. Galovičová, 
H.-J. Gabius (2005) Transient expression of 
keratin K19 is induced in originally negative 
interfollicular epidermal cells by adhesion of 
suspended cells. Int J Mol Med  16:  525–531. 
 Fischer, C., H. Sanchez-Ruderisch, M. Welzel, B. 
Wiedenmann, T. Sakai, S. André, H.-J. Gabi-
us, L. Khachigian, K.M. Detjen, S. Rosewicz 
(2005) Galectin-1 interacts with the   5  1 fi-
bronectin receptor to restrict carcinoma cell 
growth via induction of p21 and p27. J Biol 
Chem  280:  37266–37277. 
 Gabius, H.-J. (ed) (2009) The Sugar Code. Fun-
damentals of Glycosciences. Weinheim, 
Wiley-VCH. 
 Gabius, H.-J., R. Engelhardt, F. Cramer, R. Bätge, 
G.A. Nagel (1985) Pattern of endogenous lec-
tins in a human epithelial tumor. Cancer Res 
 45:  253–257. 
 Goldring, K., G.E. Jones, R. Thiagarajah, D.J. 
Watt (2002a) The effect of galectin-1 on the 
differentiation of fibroblasts and myoblasts 
in vitro. J Cell Sci  115:  355–366. 
 Goldring, K., G.E. Jones, C.A. Sewry, D.J. Watt 
(2002b) The muscle-specific marker desmin 
is expressed in a proportion of human der-
mal fibroblasts after their exposure to galec-
tin-1. Neuromuscul Disord  12:  183–186. 
2003] or in breast cancer, where stromal galectin-3 is a 
negative prognostic factor [Moisa et al., 2007]. This study 
thus broadens the experimental evidence for galectins as 
effectors for MFB generation and delineates marked ac-
tivity differences.
 In addition to cellular conversion, the formation of a 
complex scaffold rich in fibronectin and galectin-1 by 
MFBs was detected immunocytochemically. Its assumed 
bioactivity was ascertained by culturing human kerati-
nocytes on this substratum without feeder cells. Strik-
ingly, their phenotype, with a small diameter and kera-
tin-19 expression, is evocative of a low differentiation sta-
tus [Dvořánková et al., 2005], implying a beneficial role 
also in wound healing in vivo together with MFB genera-
tion [Kwon et al., 2006]. In the last part of our study, we 
report a positive effect of galectin-1 application on skin 
wound healing in rats at day 21 after surgery.
 In summary, this study describes a TGF-  -like activ-
ity of galectin-1 on MFB generation from adult dermal 
fibroblasts and detects functional divergence in this re-
spect among this family of human lectins. The matrix 
scaffold produced in vitro supports keratinocyte culture 
without feeder cells. In vivo, the application of galectin-1 
appears favorable for skin-wound healing after 3 weeks. 
Beyond wound healing, the described addition to the ac-
tivity profile of galectins, considered as biomaterials, can 
also have relevance for explaining the physiological sig-
nificance of the presence of stromal galectin in tumors.
 Acknowledgements 
 This study was supported by the Ministry of Education, Youth 
and Sports of the Czech Republic projects No. MSM 0021620806 
and 1M0538, the Charles University in Prague, the EC research 
program GlycoHIT (contract ID 260600) and the Verein zur För-
derung des biologisch-technologischen Fortschritts in der Me-
dizin e.V. (Heidelberg, Germany). The authors are grateful to Dr. 
James Dutt for the language revision and to Iva Burdová, Dr. 
Tomáš Vasilenko and Magdaléna Majnušová for excellent techni-
cal assistance. 
 Dvořánková et al. Cells Tissues Organs 2011;194:469–480 480
 Hennet, T. (2009) Diseases of glycosylation; in 
Gabius, H.-J. (ed): The Sugar Code. Funda-
mentals of Glycosciences. Weinheim, Wiley-
VCH, pp. 365–383. 
 Hinz, B. (2007) Formation and function of the 
myofibroblast during tissue repair. J Invest 
Dermatol  127:  526–537. 
 Honke, K., N. Taniguchi (2009) Animal models 
to delineate glycan functionality; in Gabius, 
H.-J. (ed): The Sugar Code. Fundamentals of 
Glycosciences. Weinheim, Wiley-VCH, pp 
385–401. 
 Kadri, T., J.-J. Lataillade, C. Doucet, A. Marie, I. 
Ernou, P. Bourin, R. Joubert-Caron, M. 
Caron, D. Lutomski (2005) Proteomic study 
of galectin-1 expression in human mesenchy-
mal stem cells. Stem Cells Dev  14:  204–212. 
 Kaltner, H., K. Seyrek, A. Heck, F. Sinowatz, H.-
J. Gabius (2002) Galectin-1 and galectin-3 in 
fetal development of bovine respiratory and 
digestive tracts. Comparison of cell type-
specific expression profiles and subcellular 
localization. Cell Tissue Res  307:  35–46. 
 Klíma, J., L. Lacina, B. Dvořánková, D. Herr-
mann, J.W. Carnwath, H. Niemann, H. Kalt-
ner, S. André, J. Motlík, H.-J. Gabius, K. 
Smetana Jr (2009) Differential regulation of 
galectin expression/reactivity during wound 
healing in porcine skin and in cultures of 
epidermal cells with functional impact on 
migration. Physiol Res  58:  873–884. 
 Kopitz, J., C. von Reitzenstein, S. André, H. Kalt-
ner, J. Uhl, V. Ehemann, M. Cantz, H.-J. 
Gabius (2001) Negative regulation of neuro-
blastoma cell growth by carbohydrate-de-
pendent surface binding of galectin-1 and 
functional divergence from galectin-3. J Biol 
Chem  276:  35917–3523. 
 Kopitz, J., M. Bergmann, H.-J. Gabius (2010) 
How adhesion/growth-regulatory galec-
tins-1 and -3 attain cell specificity: case
study defining their target on neuroblasto-
ma cells (SK-N-MC) and marked affinity 
regulation by affecting microdomain orga-
nization of the membrane. IUBMB Life  62: 
 624–628. 
 Kübler, D., C.W. Hung, T.K. Dam, J. Kopitz, S. An-
dré, H. Kaltner, M. Lohr, J.C. Manning, L. He, 
H. Wang, A. Middelberg, C.F. Brewer, J. Reed, 
W.D. Lehmann, H.-J. Gabius (2008) Phos-
phorylated human galectin-3: facile large-
scale preparation of active lectin and detec-
tion of structural changes by CD spectrosco-
py. Biochim Biophys Acta  1780:  716–722. 
 Kwon, Y.-B., H.-W. Kim, D.-H. Roh, S.-Y. Yoon, 
R.-M. Baek, J.-Y. Kim, H. Kweon, K.-G. Lee, 
Y.-H. Park, J.-H. Lee (2006) Topical applica-
tion of epidermal growth factor accelerates 
wound healing by myofibroblast prolifera-
tion and collagen synthesis in rat. J Vet Sci  7: 
 105–109. 
 Labský, J., B. Dvoránková, K. Smetana Jr., Z. 
Holíková, L. Brož, H.-J. Gabius (2003) Man-
nosides as crucial part of bioactive supports 
for cultivation of human epidermal kerati-
nocytes without feeder cells. Biomaterials 
 24:  863–872. 
 Lacina, L., K. Smetana Jr., B. Dvořánková, R. Py-
tlík, L. Kideryová, L. Kučerová, Z. Plzáková, 
J. Štork, H.-J. Gabius, S. André (2007) Stro-
mal fibroblasts from basal cell carcinoma af-
fect phenotype of normal keratinocytes. Brit 
J Dermatol  156:  819–829. 
 Lin, Y., K. Nakachi, Y. Ito, S. Kikuchi, A. Tama-
koshi, K. Yagyu, Y. Watanabe, Y. Inaba, K. 
Tajima (2009) Variations in serum trans-
forming growth factor-  1 levels with gender, 
age and lifestyle factors of healthy Japanese 
adults. Dis Markers  27:  23–28. 
 Moisa, A., P. Fritz, A. Eck, H.-D. Wehner, T. 
Mürdter, W. Simon, H.-J. Gabius, (2007) 
Growth/adhesion-reglatory tissue lectin ga-
lectin-3: stromal presence but not cytoplas-
mic/nuclear expression in tumor cells as a 
negative prognostic factor in breast cancer. 
Anticancer Res  27:  2131–2140. 
 Nagy, N., H. Legendre, O. Engels, S. André, H. 
Kaltner, K. Wasano, Y. Zick, J.C. Pector, C. 
Decaestecker, H.-J. Gabius, I. Salmon, R. Kiss 
(2003) Refined prognostic evaluation in co-
lon cancer using immunohistochemical ga-
lectin fingerprinting. Cancer  97:  1849–1858. 
 Okano, K., K. Uchida, K. Nitta, T. Hayashida 
(2008) Galectin-1 suppresses   2(I) collagen 
through Smad3 in renal epithelial cells. Cell 
Mol Life Sci  65:  3304–3311. 
 Saal, I., N. Nagy, M. Lensch, M. Lohr, J.C. Man-
ning, C. Decaestecker, S. André, R. Kiss, I. 
Salmon, H.-J. Gabius (2005) Human galec-
tin-2:expression profiling by RT-PCR/im-
munohistochemistry and its introduction as 
histochemical tool for ligand localization. 
Histol Histopathol  20:  1191–1208. 
 Sanchez-Ruderisch H., C. Fischer, K. M. Detjen, 
M. Welzel, A. Wimmel, J. C. Manning, S. 
André, H.-J. Gabius (2010) Tumor suppres-
sor p16 INK4a : downregulation of galectin-3, 
an endogenous competitor of the pro-anoi-
kis effector galectin-1, in a pancreatic carci-
noma model. FEBS J  277:  3552–3563. 
 Sarter, K., S. André, H. Kaltner, M. Lensch, C. 
Schulze, V. Urbonaviciute, G. Schett, M. 
Herrmann, H.-J. Gabius (2009) Detection 
and chromatographic removal of lipopoly-
saccharide in preparations of multifunction-
al galectins. Biochem Biophys Res Commun 
 379:  155–159. 
 Strnad, H., L. Lacina, M. Kolář, Z. Čada, Č. 
Vlček, B. Dvořánková, J. Betka, J. Plzák, M. 
Chovanec, J. Šáchová, J. Valach, M. Ur-
banová, K. Smetana Jr. (2010) Head and neck 
squamous cancer stromal fibroblasts pro-
duce growth factors influencing phenotype 
of normal human keratinocytes. Histochem 
Cell Biol  133:  201–211. 
 Sturm, A., M. Lensch, S. André, H. Kaltner, B. 
Wiedenmann, S. Rosewicz, A.U. Dignass, 
H.-J. Gabius (2004) Human galectin-2: novel 
inducer of T cell apoptosis with distinct pro-
file of caspase activation. J Immunol  173: 
 3825–3837. 
 Szabo, P., T.K. Dam, K. Smetana Jr, B. 
Dvořánková, D. Kübler, C.F. Brewer, H.-J. 
Gabius (2009) Phosphorylated human lectin 
galectin-3: analysis of ligand binding by his-
tochemical monitoring of normal/malig-
nant squamous epithelia and by isothermal 
titration calorimetry. Anat Histol Embryol 
 38:  68–75. 
 Villalobo, A., A. Nogales-Gonzalés, H.-J. Gabius 
(2006) A guide to signaling pathways con-
necting protein-glycan interaction with the 
emerging versatile effector functionality of 
mammalian lectins. Trends Glycosci Gly-
cotechnol  18:  1–37. 
 Voog, J., D.L. Jones (2010) Stem cells and the 
niche: a dynamic duo. Cell Stem Cell  6:  103–
115. 
 Wang, J., Z.-H. Lu, H.-J. Gabius, C. Rohowsky-
Kochan, R.W. Ledeen, G. Wu (2009) Cross-
linking of GM1 ganglioside by galectin-1 
mediates regulatory T cell activity involving 
TRPC5 channel activation: possible role in 
suppressing experimental autoimmune en-
cephalomyelitis. J Immunol  182:  4036–4045. 
 Yamaoka, K., S. Ohno, H. Kawasaki, K. Suzuki 
(1993) Mammalian lectin as transforming 
growth factor; in Gabius, H.-J., S. Gabius 
(eds): Lectins and Glycobiology. Heidelberg, 
Springer Verlag, pp. 492–499. 
